{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T04:22:25Z","timestamp":1788495745495,"version":"build-2803163510"},"reference-count":17,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["openrespiratorymedicinejournal.com","benthamopen.com"],"crossmark-restriction":true},"short-container-title":["TORMJ"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Pulmonary hypertension (PH) is a frequent and serious complication of advanced chronic obstructive pulmonary disease (COPD) and is associated with a poor prognosis and limited treatment options. Current management focuses on optimizing COPD care, while the role of pulmonary vasodilators remains controversial. Ensifentrine, a dual phosphodiesterase (PDE) 3\/4 inhibitor with bronchodilatory and anti-inflammatory properties, may offer a therapeutic benefit in COPD-associated PH.<\/jats:p>\n                    <jats:p>This study aims to retrospectively evaluate the effects of six months of nebulized ensifentrine on pulmonary hemodynamics and functional outcomes in patients with severe COPD and associated pre-capillary PH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We conducted a single-center, retrospective chart review of patients with GOLD stage III and IV COPD and confirmed pre-capillary PH (mean pulmonary artery pressure [mPAP] \u226520 mmHg, pulmonary vascular resistance [PVR] &gt;2 Wood units, pulmonary capillary wedge pressure \u226415 mmHg). Five patients treated with nebulized ensifentrine (3 mg twice daily) between September 2024 and May 2025 were included. Hemodynamics\n                      <jats:italic>via<\/jats:italic>\n                      right heart catheterization (RHC) and 6-minute walk distance (6MWD) were measured at baseline and at 6 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort (mean age 76 years, 60% male, mean FEV\n                      <jats:sub>1<\/jats:sub>\n                      33.4% predicted) demonstrated severe emphysema and PH (baseline mPAP 53.2 mmHg, PVR 9.5 WU, cardiac index 2.5 L\/min\/m\n                      <jats:sup>2<\/jats:sup>\n                      ). After 6 months, mean changes were as follows:\n                    <\/jats:p>\n                    <jats:p>\u2022mPAP: decrease by 1.6 mmHg<\/jats:p>\n                    <jats:p>\n                      \u2022Cardiac index: increase by 0.1 L\/min\/m\n                      <jats:sup>2<\/jats:sup>\n                    <\/jats:p>\n                    <jats:p>\u2022PVR: decrease by 1.0 WU6MWD: improved by 31 m<\/jats:p>\n                    <jats:p>\u2022mMRC dyspnea score improved from 3.6 to 3.2<\/jats:p>\n                    <jats:p>\u2022CAT score from 23 to 21.6<\/jats:p>\n                    <jats:p>\u2022DLCO increased modestly (29%\u219231.2% predicted).<\/jats:p>\n                    <jats:p>\u2022No adverse events, exacerbations, or hospitalizations were observed during this period.<\/jats:p>\n                    <jats:p>\u2022The combination of ensifentrine with roflumilast was well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Pulmonary hypertension in COPD is associated with worse outcomes, yet treatment options remain limited and uncertain. In this small retrospective case series of five patients with very severe COPD and confirmed pre-capillary PH, the addition of ensifentrine to optimized therapy was associated with modest but potentially meaningful improvements in symptoms, exercise capacity (6MWD), and select hemodynamic parameters, without worsening oxygenation. Its dual PDE3\/PDE4 inhibition and inhaled delivery provide a plausible mechanism for bronchodilation, anti-inflammatory effects, and selective pulmonary vasodilation while minimizing ventilation\u2013perfusion mismatch. However, the findings are highly preliminary given the very small sample size, lack of a control group, retrospective design, and significant selection bias, limiting generalizability and causal inference. Overall, the results are hypothesis-generating and suggest that ensifentrine may have therapeutic potential in COPD-associated PH, but larger, prospective, randomized trials are needed to confirm efficacy, safety, and its role in treatment algorithms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this retrospective study, ensifentrine was safe and was associated with modest improvements in pulmonary hemodynamics and functional status in patients with severe COPD with pre-capillary PH. These preliminary findings warrant confirmation in larger, prospective, controlled trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0118743064456019260621185404","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:33:54Z","timestamp":1782909234000},"update-policy":"https:\/\/doi.org\/10.2174\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Breath of Life Beyond Bronchodilation: Early Data on Hemodynamic and Functional Outcomes With Ensifentrine Nebulization in Severe COPD-associated Pulmonary Hypertension"],"prefix":"10.2174","volume":"20","author":[{"given":"Ramakanth","family":"Pata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Kristeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory","family":"Illies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Stocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref1","unstructured":"Chronic obstructive pulmonary disease (COPD). \n        \t2024.\n          \n         Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chronic\n            -obstructive-pulmonary-disease-(copd)"},{"key":"ref2","unstructured":"National trends in COPD. \n          2024.\n          \n         Available from: https:\/\/www\n            .cdc.gov\/copd\/php\/case-reporting\/national-trends-in-copd.html"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e2346598","DOI":"10.1001\/jamanetworkopen.2023.46598","volume":"6","author":"Boers E.","year":"2023","unstructured":"Boers E, Barrett M, Su JG, et al. \n          Global burden of chronic obstructive pulmonary disease through 2050. \n          JAMA Netw Open  \n          2023; \n          6\n          (12)\n          : e2346598.","journal-title":"JAMA Netw. Open"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.2147\/COPD.S359873","volume":"17","author":"Zhang L.","year":"2022","unstructured":"Zhang L, Liu Y, Zhao S, et al. \n          The incidence and prevalence of pulmonary hypertension in the COPD population: A systematic review and meta-analysis. \n          Int J Chron Obstruct Pulmon Dis  \n          2022; \n          17\n          : 1365-79.","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"Humbert M.","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al. \n          2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. \n          Eur Heart J  \n          2022; \n          43\n          (38)\n          : 3618-731.","journal-title":"Eur. Heart J."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"00348-2021","DOI":"10.1183\/23120541.00348-2021","volume":"8","author":"Arif R.","year":"2022","unstructured":"Arif R, Pandey A, Zhao Y, Arsenault-Mehta K, Khoujah D, Mehta S. \n          Treatment of pulmonary hypertension associated with COPD: A systematic review. \n          ERJ Open Res  \n          2022; \n          8\n          (1)\n          : 00348-2021.","journal-title":"ERJ Open Res."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","volume":"208","author":"Anzueto A.","year":"2023","unstructured":"Anzueto A, Barjaktarevic IZ, Siler TM, et al. \n          Ensifentrine, A novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: Randomized, double-blind, placebo-controlled, multicenter phase III trials (The ENHANCE Trials). \n          Am J Respir Crit Care Med  \n          2023; \n          208\n          (4)\n          : 406-16.","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","volume":"138","author":"Reddy YNV","year":"2018","unstructured":"Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA A. \n          A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. \n          Circulation  \n          2018; \n          138\n          (9)\n          : 861-70.","journal-title":"Circulation"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.chest.2020.08.019","volume":"159","author":"D\u2019Alto M.","year":"2021","unstructured":"D\u2019Alto M, Badesch D, Bossone E, et al. \n          A fluid challenge test for the diagnosis of occult heart failure. \n          Chest  \n          2021; \n          159\n          (2)\n          : 791-7.","journal-title":"Chest"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh T.A.","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. \n          2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. \n          Eur Heart J  \n          2021; \n          42\n          (36)\n          : 3599-726.","journal-title":"Eur. Heart J."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1080\/15412555.2017.1336209","volume":"14","author":"Medrek S.K.","year":"2017","unstructured":"Medrek SK, Sharafkhaneh A, Spiegelman AM, Kak A, Pandit LM. \n          Admission for COPD exacerbation is associated with the clinical diagnosis of pulmonary hypertension: Results from a retrospective longitudinal study of a veteran population. \n          COPD  \n          2017; \n          14\n          (5)\n          : 484-9.","journal-title":"COPD"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.2147\/COPD.S211841","volume":"15","author":"Blanco I.","year":"2020","unstructured":"Blanco I, Tura-Ceide O, Peinado V, Barber\u00e0 JA. \n          Updated perspectives on pulmonary hypertension in COPD. \n          Int J Chron Obstruct Pulmon Dis  \n          2020; \n          15\n          : 1315-24.","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/COPD.S385811","volume":"19","author":"Faruqi M.A.","year":"2024","unstructured":"Faruqi MA, Khan M, Mannino D. \n          Perspectives on ensifentrine and its therapeutic potential in the treatment of COPD: Evidence to date. \n          Int J Chron Obstruct Pulmon Dis  \n          2024; \n          19\n          : 11-6.","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"ref14","unstructured":"Ayres JK, Maani CV. \n          Milrinone. \n          StatPearls \n          \n          \n          2023."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"959209","DOI":"10.3389\/fimmu.2022.959209","volume":"13","author":"Liu S.F.","year":"2022","unstructured":"Liu SF, Nambiar Veetil N, Li Q, Kucherenko MM, Knosalla C, Kuebler WM. \n          Pulmonary hypertension: Linking inflammation and pulmonary arterial stiffening. \n          Front Immunol  \n          2022; \n          13\n          : 959209.","journal-title":"Front. Immunol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/01410768251366880","volume":"118","author":"Kim M.S.","year":"2025","unstructured":"Kim MS, Yon DK, Lee SW, et al. \n          Quantifying the impact of immortal time bias: Empirical evidence from meta-analyses. \n          J R Soc Med  \n          2025; \n          118\n          (9)\n          : 293-303.","journal-title":"J. R. Soc. Med."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"105641","DOI":"10.1016\/j.neubiorev.2024.105641","volume":"160","author":"Rahmati M.","year":"2024","unstructured":"Rahmati M, San Lee DKY, Lee SW, et al. \n          Physical activity and prevention of mental health complications: An umbrella review. \n          Neurosci Biobehav Rev  \n          2024; \n          160\n          : 105641.","journal-title":"Neurosci Biobehav Rev"}],"container-title":["The Open Respiratory Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V20\/e18743064456019\/e18743064456019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V20\/e18743064456019\/e18743064456019.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openrespiratorymedicinejournal.com\/contents\/volumes\/V20\/e18743064456019\/e18743064456019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T12:36:15Z","timestamp":1782909375000},"score":1,"resource":{"primary":{"URL":"https:\/\/openrespiratorymedicinejournal.com\/VOLUME\/20\/ELOCATOR\/e18743064456019\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.2174\/0118743064456019260621185404","relation":{},"ISSN":["1874-3064"],"issn-type":[{"value":"1874-3064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-12-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e18743064456019"}}